1. Home
  2. OSUR vs MGTX Comparison

OSUR vs MGTX Comparison

Compare OSUR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

N/A

Current Price

$3.51

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

N/A

Current Price

$12.84

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSUR
MGTX
Founded
2000
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.6M
1.2B
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
OSUR
MGTX
Price
$3.51
$12.84
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$3.00
$24.57
AVG Volume (30 Days)
439.4K
700.7K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
1.30
Revenue
$167,064,000.00
$81,391,000.00
Revenue This Year
$4.48
$141.38
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
$9.82
Revenue Growth
N/A
144.57
52 Week Low
$2.08
$6.62
52 Week High
$4.58
$15.35

Technical Indicators

Market Signals
Indicator
OSUR
MGTX
Relative Strength Index (RSI) 41.82 40.79
Support Level $2.86 $12.39
Resistance Level $4.29 $15.33
Average True Range (ATR) 0.13 0.55
MACD -0.01 -0.23
Stochastic Oscillator 48.84 10.74

Price Performance

Historical Comparison
OSUR
MGTX

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: